OUR FOCUS
Fueling The Advancement of Healthcare Technology
With new technologies transforming early detection and making prognosis/disease monitoring a critical element of patient care, the Diagnostics and Tools sector is making great advances from research to clinical, elevating the category as a trusted outsourcing partner for Biopharma.
Our Diagnostics and Tools team partners with established and emerging companies as a trusted advisor across capital formation and M&A strategy.
Recent transactions
$70 Million
Exclusive Financial Advisor
Series B Financing and Strategic Collaboration with Quest Diagnostics
November 2023
$350 Million
Joint Bookrunner
Follow-On
May 2023
$117 Million
Joint Bookrunner
Follow-On
January 2023
$400 MILLION
Joint Bookrunner
Follow-On
November 2022
